Results 41 to 50 of about 12,661 (240)
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC
Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu +11 more
wiley +1 more source
Цель. Идентифицировать аллели 3 генов локуса HLA класса II в двух группах бурят (больных СД 1 и здоровых) с последующим определением диабетогенных гаплотипов.
Ivan Ivanovich Dedov +6 more
doaj +1 more source
Insilico prediction and functional analysis of nonsynonymous SNPs in human CTLA4 gene
The CTLA4 receptor is an immune checkpoint involved in the downregulation of T cells. Polymorphisms in this gene have been found to be associated with different diseases like rheumatoid arthritis, autosomal dominant immune dysregulation syndrome ...
M. Irfan +4 more
semanticscholar +1 more source
We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma.
David L. Bajor +17 more
doaj +1 more source
Purpose Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma.
A. Rose +12 more
semanticscholar +1 more source
CTLA-4 blocking therapeutic antibodies are currently under investigation in head and neck squamous cell carcinoma (HNSCC). A better understanding of the epigenetic regulation of the CD28 superfamily members CD28, CTLA-4, and ICOS and their B7 ligands ...
Luka de Vos +9 more
doaj +1 more source
Combination therapy with inhibitors of cytotoxic T lymphocyte-associated protein (CTLA)4 and programmed death (PD)-1 has demonstrated efficacy in cancer patients. However, there is little information on CTLA4 and PD-1 expression levels and their clinical
Jian-Nan Liu +5 more
semanticscholar +1 more source
Background/aim: T-cell immunotherapies are rapidly gaining grounds in clinical success. Presently, there is first-to-market knowledge on the translation of research scale methods to clinical and commercial scales.
Matthew Li +5 more
doaj +1 more source
Background This study compared response rates and outcomes of combined radiotherapy and immunotherapy (iRT) based on the type of checkpoint inhibitor (anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) vs antiprogrammed death-1 (PD1)) for ...
Dawei Chen +10 more
semanticscholar +1 more source
The immune checkpoint inhibitor (ICI) ipilimumab has revolutionized the treatment of patients with different cancer histologies, including melanoma, renal cell carcinoma, and non-small cell lung carcinoma.
N. Mason +8 more
semanticscholar +1 more source

